Blinded independent central review analysis showed a 6.8-month improvement in median progression-free survival with sunitinib versus placebo in patients with pancreatic neuroendocrine tumors. The 5-year overall survival (OS) results continued to favor sunitinib, although not statistically significant. Adjustment for treatment crossover in the placebo arm confirmed OS benefit of sunitinib therapy.
http://ift.tt/2fDAvBT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου